Here we provide a review of the microarray technology, including the introduction of array platforms, experimental designs, RNA isolation and amplification, array hybridization, and data analysis.
With recent advances in microarray technology, including genomics, proteomics, and metabolomics, it brings a great challenge for integrating this "-omics" data to analysis complex disease.
RNA-Seq studies have several advantages over microarray technology, including whole transcriptome analysis, better reproducibility, and a larger dynamic range of expression [ 8, 9].
While these two examples are yeast specific, other model organisms have also been used to study meiosis with microarray technology, including fruit flies (Drosophila melanogaster), mice (Mus musculus), nematodes (Caenorhabiditis elegans) and rats (Rattus rattus) [ 8- 11].
Regarding the question of normal distribution, we looked over Dr. Churchill's papers dealing with microarray technology, including Cui et al. Biostatistics (2005) [a], 6 :59–75, Cui and Churchill, Genome Biology (2003), 4 :210 [b], Churchill, BioTechniques (2004), 37 :173 [c], Kerr, Churchill.
Various human disorders that affect the SM tissue have been analyzed using microarray technology, including disuse atrophy [ 1], myositis [ 2, 3], Duchenne muscular dystrophy (DMD) [ 4- 6] and others [ 7- 9].
Recent advances in microarray technology including high density SNP (single nucleotide polymorphism) profiling have provided a novel approach to evaluate CNA across the genome of patient tissue specimens as a potential diagnostic tool for tumor classification.
Such an approach has several advantages over microarray technology, including the ability to detect novel transcripts and transcript isoforms, distinguish between closely related paralogous sequences, and quantify expression in a "digital" rather than "analog" manner [ 13, 16- 18].
However, the recent advent of RNA sequencing (RNA-seq) technologies offers unprecedented opportunities for gene expression analysis previously unavailable for microarray technology, including unbiased whole-transcriptome profiling, the analysis of sense and antisense transcription, the characterisation of new classes of RNA, and the identification of novel mRNA splice variants [ 22, 23].
We describe here an HCV genotyping assay based on liquid microarray technology and including 16 hybridization probes specific for different HCV genotypes and subtypes and one set of primers for each of the two regions most frequently used for HCV detection and genotyping (5'UTR and NS5B).
